OXYMETAZOLINE

US Approved OTC

First approved in 1964

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H24N2O
Molecular Weight	260.3746
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=C(O)C(C)=C1CC2=NCCN2)C(C)(C)C

InChI

InChIKey=WYWIFABBXFUGLM-UHFFFAOYSA-N

InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C16H24N2O
Molecular Weight	260.3746
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB00935
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/monograph/oxymetazoline-hydrochloride.html

Oxymetazoline is an adrenergic alpha-agonist, direct acting sympathomimetic, used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis. Oxymetazoline is self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. Oxymetazoline is available over-the-counter as a topical decongestant in the form of oxymetazoline hydrochloride in nasal sprays such as Afrin, Operil, Dristan, Dimetapp, oxyspray, Facimin, Nasivin, Nostrilla, Sudafed OM, Vicks Sinex, Zicam, SinuFrin, and Mucinex Full Force. Due to its vasoconstricting properties, oxymetazoline is also used to treat nose bleeds and eye redness.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/20030735 \| https://www.ncbi.nlm.nih.gov/pubmed/11844675	Agonist 2678	4.96 null [pEC50]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: https://www.drugbank.ca/drugs/DB00935 \| https://www.ncbi.nlm.nih.gov/pubmed/24365159 \| https://www.ncbi.nlm.nih.gov/pubmed/1974694	Partial Agonist 290	0.29 nM [Ki]
Serotonin 1a (5-HT1a) receptor 172 Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2678	7.73 null [pEC50]
Serotonin 1d (5-HT1d) receptor 52 Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678720	Agonist 2678	7.35 null [pEC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Nasal congestion 26 Sources: https://www.drugs.com/ppa/oxymetazoline-nasal.html	Palliative		Approved 8429	Oxymetazoline Hydrochloride Approved Use Temporary relief of nasal congestion (due to a cold, hay fever, or other upper respiratory allergies) and sinus congestion/pressure. Launch Date 1989
Eye irritations 2 Sources: https://www.drugs.com/cdi/oxymetazoline-drops.html	Primary		Approved 8429	OCUCLEAR Approved Use Relief of redness of eye due to minor eye irritations Launch Date 1986

C_max

Value	Dose	Co-administered	Analyte	Population
60.5 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.78 ng/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
895 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf	20 mg single, topical dose: 20 mg route of administration: Topical experiment type: SINGLE co-administered:		OXYMETAZOLINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4.24 ng × h/mL DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.23 h DRUG LABEL https://www.fda.gov/media/98992/download	0.3 mg single, nasal dose: 0.3 mg route of administration: Nasal experiment type: SINGLE co-administered: Tetracaine	Tetracaine	OXYMETAZOLINE unknown	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	Other AEs: Hypertensive crisis... Other AEs: Hypertensive crisis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	Disc. AE: Application site dermatitis, Application site erythema... AEs leading to discontinuation/dose reduction: Application site dermatitis (1.4%) Application site erythema (0.5%) Application site pain (0.5%) Application site dryness (0.2%) Hypoesthesia (0.2%) Paresthesia (0.2%) Rash (0.2%) Urticaria (0.2%) Photosensitivity reaction (0.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
1.5 % 2 times / day multiple, topical Highest studied dose Dose: 1.5 %, 2 times / day Route: topical Route: multiple Dose: 1.5 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	unhealthy, adult Health Status: unhealthy Condition: Erythema Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/29462230	Sources: https://pubmed.ncbi.nlm.nih.gov/29462230

AEs

AE	Significance	Dose	Population
Hypertensive crisis	1 patient	0.05 % single, intranasal Dose: 0.05 % Route: intranasal Route: single Dose: 0.05 % Sources: https://pubmed.ncbi.nlm.nih.gov/23679077	unhealthy, 4 years n = 1 Health Status: unhealthy Age Group: 4 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23679077
Application site dryness	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Hypoesthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Paresthesia	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Photosensitivity reaction	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Rash	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Urticaria	0.2% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site erythema	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site pain	0.5% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914
Application site dermatitis	1.4% Disc. AE	1 % 1 times / day multiple, topical Dose: 1 %, 1 times / day Route: topical Route: multiple Dose: 1 %, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29409914	unhealthy, 53.1 years (range: 19–81 years) n = 440 Health Status: unhealthy Condition: Erythema Age Group: 53.1 years (range: 19–81 years) Sex: M+F Population Size: 440 Sources: https://pubmed.ncbi.nlm.nih.gov/29409914

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 781 substrate 1737	inhibitor 1767 substrate 1037	inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278	CYP2C19 991 CYP1A2 1054 CYP2B6 664 CYP2C8 693 CYP2C18 138 CYP2E1 667 UGT1A9 380 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A6 307 UGT1A8 283 UGT1A10 291 UGT2B4 249 UGT2B7 389 UGT2B15 203 UGT2B17 213	CYP1A2 701 CYP2B6 547

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208552s000lbl.pdf#page=6 Page: 6.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C18 138	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
CYP3A4 1737	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/ Page: 7.0	no
UGT1A1 418	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A10 291	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A3 422	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A4 347	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A6 307	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A8 283	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B15 203	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B17 213	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B4 249	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT2B7 389	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	no
UGT1A9 380	substrate 3367 Sources: https://jpharmsci.org/article/S0022-3549(15)32302-9/abstract	yes
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0	yes	no (co-administration study) Comment: concomitant oral moderate CYP2C19 inhibitors (e.g., esomeprazole, fluoxetine, and omeprazole): the results did not indicate an increase in oxymetazoline exposure associated with coadministration of oral moderate CYP2C19 inhibitors Sources: https://pubmed.ncbi.nlm.nih.gov/21177487/; Page: 7.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208552Orig1s000PharmR.pdf#page=19 Page: 19.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:7862	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7862
ChemicalBook	CB0371500	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0371500
ZINC	ZINC000000057435	http://zinc15.docking.org/substances/ZINC000000057435
eMolecules	902254	https://www.emolecules.com/cgi-bin/more?vid=902254

PubMed

Title	Date	PubMed
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.	1999 May	10217294
Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.	2001 Aug	11481271
The effect of inferior turbinate hypertrophy on nasal spray distribution to the middle meatus.	2001 Dec	11843929
Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists.	2001 Jul 6	11331292
Reduced baroreceptor sensitivity during hypotension in ANP-knockout mice.	2001 Mar	11294595
Inhibition of synovial plasma extravasation by preemptive administration of an antiinflammatory irrigation solution in the rat knee.	2001 May	11323366
[Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons].	2001 Nov	11774707
Renal actions of the alpha2-adrenoceptor agonist, xylazine, in the anaesthetised rat.	2001 Oct	16032189
Endothelial G protein beta-subunits trigger nitric oxide-but not endothelium-derived hyperpolarizing factor-dependent dilation in rabbit resistance arteries.	2001 Oct 12	11597995
Vasocontractile effects of alpha 2-adrenergic agonists associated with intracellular calcium release.	2002	12434541
Endothelial inhibitory modulation on the contractile responses to alpha 2-adrenergic agonists.	2002	12434540
The stability of oxymetazoline hydrochloride in aqueous solution.	2002 Jan-Feb	12026107
[The relationship between ostial patency and medical treatment in acute maxillary sinusitis: an experimental study].	2002 Jul-Aug	12422083
Contractile responses of the rat vas deferens after epithelium removal.	2002 May 3	12269404
Search of antimicrobial activity of selected non-antibiotic drugs.	2002 Nov-Dec	12669766
Pertussis toxin converts hyperpolarizations caused by alpha(2)-adrenoceptor agonists containing an imidazoline moiety into depolarizations in MIN 6 cells.	2002 Sep	12172702
Topical nasal anesthesia for transnasal fiberoptic laryngoscopy: a prospective, double-blind, cross-over study.	2003 Apr	12707645
Evidence for nonadrenoceptor responses to imidazoline derivatives in the porcine isolated rectal artery.	2003 Dec	15028617
Alpha(2A)-adrenergic versus imidazoline receptor controversy in rilmenidine's action: alpha(2A)-antagonism in humans versus alpha(2A)-agonism in rabbits.	2003 Dec	15028600
Effects of acute, repeated and chronic variable stress on in vivo tyrosine hydroxylase activity and on alpha(2)-adrenoceptor sensitivity in the rat brain.	2003 Dec	14660060
5-HT7 receptor-mediated relaxation of the oviduct in nonpregnant proestrus pigs.	2003 Feb 14	12586216
Topical nasal anesthesia and laryngopharyngeal sensory testing: a prospective, double-blind crossover study.	2003 Jan	12537052
Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons.	2003 Mar	12606912
[The use of oxymetazoline in nasal endoscopic sinus surgery].	2003 May	12916356
[Acute exposure to imidazoline derivatives in children].	2003 Nov-Dec	14685449
[Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].	2003 Oct	14523532
Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis.	2003 Sep	14579657
Bulk is a determinant of oxymetazoline affinity for the alpha1A-adrenergic receptor.	2004	15512845
Chronic rhinosinusitis: management for optimal outcomes.	2004	15182211
Intranasal drug delivery: an alternative to intravenous administration in selected emergency cases.	2004 Apr	15039670
Antimuscarinic action of oxymetazoline on human intraocular muscles.	2004 Aug	15321027
Behavioral effects of serotonin and serotonin agonists in two crayfish species, Procambarus clarkii and Orconectes rusticus.	2004 Dec	15596395
Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions.	2004 Jan	14726922
Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study.	2005 Apr	15806055
Pulmonary edema following phenylephrine intranasal spray administration during the induction of general anesthesia in a child.	2005 Apr 30	15861508
Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction.	2005 Feb	15689767
An assessment for the presence of bacterial contamination of Venturi principle atomizers in a clinical setting.	2005 Jan-Feb	15794070
[Investigation of the effect of oxymetazoline on the duration of rhinitis].	2005 Oct 13	16270513
Pharmacological characterization of postjunctional alpha-adrenoceptors in human nasal mucosa.	2005 Sep-Oct	16270605
Human breast cell lines exhibit functional alpha2-adrenoceptors.	2006 Jul	16292538
Simultaneous determination of triamcinolone acetonide and oxymetazoline hydrochloride in nasal spray formulations by HPLC.	2006 Mar 18	16297589

Patents

Sample Use Guides

In Vivo Use Guide

Pediatric Patients Nasal Congestion Intranasal For self-medication in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed. Adults Nasal Congestion Intranasal For self-medication: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily. Conjunctival Congestion Ophthalmic For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Route of Administration: Nasal

In Vitro Use Guide

Oxymetazoline had a concentration-dependent inhibitory effect on cultured human nasal CBF from 0.25 to 2.00 g/L.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:48:33 GMT 2023` Edited by `admin` on `Sat Dec 16 16:48:33 GMT 2023`
Record UNII	8VLN5B44ZY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXYMETAZOLINE

Official Name

English

NASACON

Brand Name

English

AFRIN

Brand Name

English

OPERIL

Brand Name

English

OXYMETAZOLINE [VANDF]

Common Name

English

Oxymetazoline [WHO-DD]

Common Name

English

oxymetazoline [INN]

Common Name

English

PHENOL, 3-((4,5-DIHYDRO-1H-IMIDAZOL-2-YL)METHYL)-6-(1,1-DIMETHYLETHYL)-2,4-DIMETHYL-

Systematic Name

English

OXYMETAZOLINE [HSDB]

Common Name

English

6-TERT-BUTYL-3-(2-IMIDAZOLIN-2-YLMETHYL)-2,4-DIMETHYLPHENOL

Systematic Name

English

OXYMETAZOLINE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR01AA05